Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2010.

23 Apr 2010

European Patent Office intends to grant patent for Intezyne's IVECT Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne's breakthrough drug delivery technology, the IVECT Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues.

23 Apr 2010

Interdisciplinary research leads to first known use of smart nanofilm on living tissue

Louisiana Tech students Mridhula Thangaraj and Chris Monceaux will participate in a symposium on 'Regenerative Medicine - Wound Healing' at the 2010 Experimental Biology meeting, April 24-28 at the Anaheim Convention Center.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.

22 Apr 2010

Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases

Delcath Systems, Inc., a development stage, oncology-focused, specialty pharmaceutical and medical device company, announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study's primary endpoint of extended hepatic progression-free survival (hPFS) in patients with melanoma metastases to the liver based on an independently corroborated intent-to-treat analysis.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm Inc. today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

21 Apr 2010

DSM Biomedical, CID partner on use of ComfortCoat Hydrophilic coating technology

DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE marked and launched on the European market last month.

21 Apr 2010

Lipocine announced receipt of $2M development milestone payment from Abbott

Lipocine Inc. announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone.

21 Apr 2010

3M Littmann Model 3200 and Zargis Cardioscan software receive red dot design award

3M and Zargis Medical Corp., today announced that the 3M Littmann Electronic Stethoscope Model 3200 and the Zargis Cardioscan software recently received two industry awards for design and innovation: the "red dot: best of the best" award for product design, given by the Design Zentrum Nordrhein Westfalen, an internationally known design institution located in Essen, Germany, and the Medical Design Excellence Award, sponsored by Medical Device & Diagnostic Industry magazine.

21 Apr 2010

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.

21 Apr 2010

FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths. Commercial shipments of the product have already commenced.

21 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Investment report on Generex Biotechnology from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

19 Apr 2010

New drug to stop the growth of prostate cancer tumors investigated

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

17 Apr 2010

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

Drug Delivery News and Research

Further Reading

Cipher Pharmaceuticals' first-quarter total revenue up 52%

European Patent Office intends to grant patent for Intezyne's IVECT Method

Interdisciplinary research leads to first known use of smart nanofilm on living tissue

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

DSM Biomedical, CID partner on use of ComfortCoat Hydrophilic coating technology

Lipocine announced receipt of $2M development milestone payment from Abbott

3M Littmann Model 3200 and Zargis Cardioscan software receive red dot design award

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Investment report on Generex Biotechnology from MicroStockProfit.com

New drug to stop the growth of prostate cancer tumors investigated

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News